BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fight Against Resistance To Antibiotics - Infectio Diagnostic Inc. Receives FDA Approval


10/19/2005 5:10:31 PM

QUEBEC CITY, March 22 /PRNewswire/ -- Infectio Diagnostic Inc. (IDI) has just received clearance from the US Food and Drug Administration (FDA) to market its new ultra-rapid test (IDI-MRSA(TM)) for detecting methicillin- resistant Staphylococcus aureus (MRSA). This is the first MRSA test cleared by the USFDA for use directly on clinical specimens. This is the second IDI test cleared by the FDA.

IDI-MRSA(TM) is also the only test licensed by Health Canada for the detection of MRSA directly from clinical specimens. The license was received in November 2003.

MRSA is one of the main causes of nosocomial infections which are responsible for the death of thousands of hospitalized patients every year. Today, healthcare institutions are spending huge amount of money to fight and prevent the spread of these infections. The ultra-rapid identification of MRSA will significantly reduce such costs. With IDI-MRSA(TM), an answer is obtained within one hour, whereas the traditional method takes 2 to 5 days.

The President of IDI, Jean-Pierre Gayral, states "We have accomplished a worldwide breakthrough. Our test is the first and only one that allows for the immediate detection of MRSA. It provides the medical community with an essential tool for the prevention and control of these infections. This milestone confirms our position at the leading edge of technology in diagnostic products."

IDI recently signed a partnership agreement with Chiron Corporation of Emeryville, California, for the detection of microbial contaminants in platelet units. IDI also just granted a license to bioMerieux, a worldwide leader in clinical microbiology.

IDI is a private biotechnology company specialized in the development of molecular diagnostic tests for bacterial, fungal and parasitic infections. The company's head office is located in Quebec City (Canada).

INFECTIO DIAGNOSTIC INC.

CONTACT: Diane Periard, Assistant to the President and CEO, (418)681-4343, extension 229



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES